Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Journal für Urologie und Urogynäkologie/Österreich 2/2021

14.04.2021 | Originalien

Benigne Prostatahyperplasie: Bis zu welchem Zeitpunkt kann man konservativ behandeln?

verfasst von: PD Dr. Frank Strittmatter

Erschienen in: Journal für Urologie und Urogynäkologie/Österreich | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten
share
TEILEN

Zusammenfassung

Das benigne Prostatasyndrom (BPS) ist häufig mit einer vergrößerten Prostata und einer damit verbundenen Auslassobstruktion vergesellschaftet und führt zu Symptomen des unteren Harntraktes („lower urinary tract symptoms“, LUTS). Es handelt sich aufgrund seiner Häufigkeit um eine Volkskrankheit von großer Relevanz. In den letzten Jahren hat die Möglichkeit der medikamentösen Therapie die Häufigkeit der operativen Intervention stark beeinflusst. Trotz zahlreicher nationaler und internationaler Leitlinienempfehlungen zur Behandlung von Patienten mit BPH ist die Frage: „Bis wann kann ich konservativ bleiben?“ nicht ausreichend geklärt.
Literatur
1.
Zurück zum Zitat McConnell JD et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349(25):2387–2398 CrossRef McConnell JD et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349(25):2387–2398 CrossRef
2.
Zurück zum Zitat Roehrborn CG (2008) BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int 101(Suppl 3):17–21 CrossRef Roehrborn CG (2008) BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int 101(Suppl 3):17–21 CrossRef
3.
Zurück zum Zitat Sebastianelli A, Gacci M (2018) Current status of the relationship between metabolic syndrome and lower urinary tract symptoms. Eur Urol Focus 4(1):25–27 CrossRef Sebastianelli A, Gacci M (2018) Current status of the relationship between metabolic syndrome and lower urinary tract symptoms. Eur Urol Focus 4(1):25–27 CrossRef
4.
Zurück zum Zitat Berges R (2008) Epidemiology of benign prostatic syndrome. Associated risks and management data in German men over age 50. Urologe A 47(2):141–148 CrossRef Berges R (2008) Epidemiology of benign prostatic syndrome. Associated risks and management data in German men over age 50. Urologe A 47(2):141–148 CrossRef
5.
Zurück zum Zitat Chapple CR, Roehrborn CG (2006) A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 49(4):651–658 CrossRef Chapple CR, Roehrborn CG (2006) A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 49(4):651–658 CrossRef
6.
Zurück zum Zitat Isaacs JT (1994) Etiology of benign prostatic hyperplasia. Eur Urol 25(Suppl 1):6–9 CrossRef Isaacs JT (1994) Etiology of benign prostatic hyperplasia. Eur Urol 25(Suppl 1):6–9 CrossRef
7.
Zurück zum Zitat Gratzke C et al (2015) EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 67(6):1099–1109 CrossRef Gratzke C et al (2015) EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 67(6):1099–1109 CrossRef
8.
Zurück zum Zitat Bach T, Heitz M, Bruns T (2020) Benign prostatic hyperplasia : new and treatment-relevant aspects from the DGU guidelines. Urologe A 59(5):544–549 CrossRef Bach T, Heitz M, Bruns T (2020) Benign prostatic hyperplasia : new and treatment-relevant aspects from the DGU guidelines. Urologe A 59(5):544–549 CrossRef
9.
Zurück zum Zitat Strittmatter F et al (2013) Current pharmacological treatment options for male lower urinary tract symptoms. Expert Opin Pharmacother 14(8):1043–1054 CrossRef Strittmatter F et al (2013) Current pharmacological treatment options for male lower urinary tract symptoms. Expert Opin Pharmacother 14(8):1043–1054 CrossRef
10.
Zurück zum Zitat Michel MC, Goepel M (2001) Lower urinary tract symptoms suggestive of benign prostatic obstruction—what’s the long-term effectiveness of medical therapies? Eur Urol 39(Suppl 3):20–25 CrossRef Michel MC, Goepel M (2001) Lower urinary tract symptoms suggestive of benign prostatic obstruction—what’s the long-term effectiveness of medical therapies? Eur Urol 39(Suppl 3):20–25 CrossRef
11.
Zurück zum Zitat Cindolo L et al (2015) Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol 68(3):418–425 CrossRef Cindolo L et al (2015) Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol 68(3):418–425 CrossRef
12.
Zurück zum Zitat Rosen R et al (2003) Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 44(6):637–649 CrossRef Rosen R et al (2003) Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 44(6):637–649 CrossRef
13.
Zurück zum Zitat D’Agate S et al (2020) Model-based meta-analysis of individual International Prostate Symptom Score trajectories in patients with benign prostatic hyperplasia with moderate or severe symptoms. Br J Clin Pharmacol 86(8):1585–1599 CrossRef D’Agate S et al (2020) Model-based meta-analysis of individual International Prostate Symptom Score trajectories in patients with benign prostatic hyperplasia with moderate or severe symptoms. Br J Clin Pharmacol 86(8):1585–1599 CrossRef
14.
Zurück zum Zitat Izard J, Nickel JC (2011) Impact of medical therapy on transurethral resection of the prostate: two decades of change. BJU Int 108(1):89–93 CrossRef Izard J, Nickel JC (2011) Impact of medical therapy on transurethral resection of the prostate: two decades of change. BJU Int 108(1):89–93 CrossRef
15.
Zurück zum Zitat Presicce F, De Nunzio C, Tubaro A (2018) Clinical implications for the early treatment of benign prostatic enlargement (BPE): a systematic review. Curr Urol Rep 19(9):70 CrossRef Presicce F, De Nunzio C, Tubaro A (2018) Clinical implications for the early treatment of benign prostatic enlargement (BPE): a systematic review. Curr Urol Rep 19(9):70 CrossRef
16.
Zurück zum Zitat Presicce F et al (2017) The influence of the medical treatment of LUTS on benign prostatic hyperplasia surgery: do we operate too late? Minerva Urol Nefrol 69(3):242–252 PubMed Presicce F et al (2017) The influence of the medical treatment of LUTS on benign prostatic hyperplasia surgery: do we operate too late? Minerva Urol Nefrol 69(3):242–252 PubMed
17.
Zurück zum Zitat Presicce F, De Nunzio C, Tubaro A (2017) Can long-term LUTS/BPH pharmacological treatment alter the outcomes of surgical intervention? Curr Urol Rep 18(9):72 CrossRef Presicce F, De Nunzio C, Tubaro A (2017) Can long-term LUTS/BPH pharmacological treatment alter the outcomes of surgical intervention? Curr Urol Rep 18(9):72 CrossRef
18.
Zurück zum Zitat Reynard JM, Shearer RJ (1999) Failure to void after transurethral resection of the prostate and mode of presentation. Urology 53(2):336–339 CrossRef Reynard JM, Shearer RJ (1999) Failure to void after transurethral resection of the prostate and mode of presentation. Urology 53(2):336–339 CrossRef
19.
Zurück zum Zitat Djavan B et al (1997) Urodynamic assessment of patients with acute urinary retention: is treatment failure after prostatectomy predictable? J Urol 158(5):1829–1833 CrossRef Djavan B et al (1997) Urodynamic assessment of patients with acute urinary retention: is treatment failure after prostatectomy predictable? J Urol 158(5):1829–1833 CrossRef
20.
Zurück zum Zitat Blatt AH et al (2012) Transurethral prostate resection in patients with hypocontractile detrusor – what is the preditctive value of ultrastructural detrusor changes? J Urol 188(6):2294–2299 CrossRef Blatt AH et al (2012) Transurethral prostate resection in patients with hypocontractile detrusor – what is the preditctive value of ultrastructural detrusor changes? J Urol 188(6):2294–2299 CrossRef
Metadaten
Titel
Benigne Prostatahyperplasie: Bis zu welchem Zeitpunkt kann man konservativ behandeln?
verfasst von
PD Dr. Frank Strittmatter
Publikationsdatum
14.04.2021
Verlag
Springer Vienna
Erschienen in
Journal für Urologie und Urogynäkologie/Österreich / Ausgabe 2/2021
Print ISSN: 1023-6090
Elektronische ISSN: 1680-9424
DOI
https://doi.org/10.1007/s41972-021-00133-x